Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Alpha Tau Medical Ltd DRTS

Alternate Symbol(s):  DRTSW

Healthcare Biotechnology
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending... see more

Current News (NDAQ:DRTS)

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

GlobeNewswire 13 days ago

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

GlobeNewswire January 5, 2026

Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference

GlobeNewswire December 18, 2025

Sidoti Events, LLC's Year-End Virtual Investor Conference

ACCESS Newswire December 9, 2025

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

GlobeNewswire December 9, 2025

Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium

GlobeNewswire December 4, 2025

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer

GlobeNewswire December 2, 2025

Alpha Tau to Participate in December Investor Conferences

GlobeNewswire December 1, 2025

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 20, 2025
View More News ››

Opinion & Analysis (NDAQ:DRTS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:DRTS)

DRTS..... been awhile...early a.m runner

Big ...huge waterfall......green to red move you've all been had ....again!!!!
Iseneschal - August 18, 2023

DRTS ....Mr. Maggot wants all your warrants ; )

Buy odas keep poping up out of no where...LoL Gotta go
Iseneschal - March 24, 2022

DRTS wts ...... sell to the MM's 50K shares buy oda !

Fill yer boots !
Iseneschal - March 24, 2022

DRTS ...now the big bid shows up .... 15K wanted

LoL
Iseneschal - March 24, 2022

DRTS .... no sellers & no buyers ; )

Something is going to happen ..... start the clock & place ur bets !
Iseneschal - March 24, 2022

DRTS ..... 3 times lucky ?

Over $16 again
Iseneschal - March 24, 2022
View more Bullboard ››

Tidal Care Inc.

Tidal Care Inc.

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the ...
View More »

Podcasts